We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
-5.07%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$4.94B
AUM Growth
-$256M
(-4.9%)
Cap. Flow
+$155M
Cap. Flow
% of AUM
3.13%
Top 10 Holdings %
Top 10 Hldgs %
23%
Holding
310
New
46
Increased
109
Reduced
88
Closed
39
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$52.6M |
| 2 |
UnitedHealth
UNH
|
+$48.5M |
| 3 |
Eli Lilly
LLY
|
+$40.2M |
| 4 |
Bank of America
BAC
|
+$33.6M |
| 5 |
Pfizer
PFE
|
+$32.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TWX
Time Warner Inc
TWX
|
+$55.2M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$45M |
| 3 |
Zimmer Biomet
ZBH
|
+$35.5M |
| 4 |
Cooper Companies
COO
|
+$35.5M |
| 5 |
Roper Technologies
ROP
|
+$31.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.89% |
| 2 | Technology | 24.22% |
| 3 | Financials | 21.01% |
| 4 | Communication Services | 9.7% |
| 5 | Consumer Discretionary | 6.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACOR
226
DELISTED
Acorda Therapeutics
ACOR
| $1.24M | 0.03% |
390
-55
| -12% | -$213K |
|
227
Sabre
SABR
$743M
| $1.13M | 0.02% |
+41,515
| New | +$1.12M |
|
|
ATHN
228
DELISTED
Athenahealth, Inc.
ATHN
| $1.1M | 0.02% |
8,267
-47,921
| -85% | -$6.25M |
|
229
HDFC Bank
HDB
$121B
| $1.09M | 0.02% |
71,608
| – | – |
|
|
KEYW
230
DELISTED
The KEYW Holding Corporation
KEYW
| $971K | 0.02% |
157,894
-32,708
| -17% | -$265K |
|
|
SHPG
231
DELISTED
Shire pic
SHPG
| $934K | 0.02% |
4,553
-445
| -9% | -$106K |
|
232
Altria Group
MO
$125B
| $843K | 0.02% |
15,500
+1,500
| +11% | +$80.4K |
|
|
VIVO
233
DELISTED
Meridian Bioscience Inc
VIVO
| $732K | 0.01% |
42,800
| – | – |
|
234
Acadia Pharmaceuticals
ACAD
$4.45B
| $705K | 0.01% |
21,333
-9,142
| -30% | -$380K |
|
|
HSTO
235
DELISTED
Histogen Inc. Common Stock
HSTO
| $695K | 0.01% |
783
| – | – |
|
|
TBRA
236
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
| $653K | 0.01% |
67,570
+33,510
| +98% | +$470K |
|
237
Pathward Financial
CASH
$1.87B
| $651K | 0.01% |
46,722
-9,225
| -16% | -$141K |
|
|
CAMP
238
DELISTED
CalAmp Corp.
CAMP
| $647K | 0.01% |
+1,748
| New | +$688K |
|
239
Pacira BioSciences
PCRX
$1.05B
| $612K | 0.01% |
14,890
-20,030
| -57% | -$1.23M |
|
|
SGYP
240
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $607K | 0.01% |
+114,530
| New | +$886K |
|
|
ISEE
241
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $580K | 0.01% |
+14,316
| New | +$758K |
|
|
MODN
242
DELISTED
MODEL N, INC.
MODN
| $576K | 0.01% |
57,651
-13,615
| -19% | -$147K |
|
|
MDVN
243
DELISTED
MEDIVATION, INC.
MDVN
| $558K | 0.01% |
13,141
-16,711
| -56% | -$828K |
|
244
ProQR Therapeutics
PRQR
$248M
| $510K | 0.01% |
+35,000
| New | +$586K |
|
245
Rocket Pharmaceuticals
RCKT
$343M
| $469K | 0.01% |
12,478
-5,022
| -29% | -$231K |
|
|
SIVB
246
DELISTED
SVB Financial Group
SIVB
| $436K | 0.01% |
3,774
+590
| +19% | +$79K |
|
247
Alkermes
ALKS
$8.42B
| $419K | 0.01% |
7,134
-276
| -4% | -$18.2K |
|
248
Prosperity Bancshares
PB
$8.82B
| $406K | 0.01% |
8,272
| – | – |
|
|
QIWI
249
DELISTED
QIWI PLC
QIWI
| $279K | 0.01% |
17,317
+1,700
| +11% | +$41.6K |
|
|
AFMD
250
DELISTED
Affimed
AFMD
| $269K | 0.01% |
4,355
-1,233
| -22% | -$153K |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q3 2015 Portfolio in Review
As of Q3 2015, Polar Capital held 310 positions worth $4.94B, down 4.9% from $5.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Polar Capital deployed $155M of net new capital in Q3 2015, opening 46 new positions and adding to 109 existing holdings. Its largest new stake was Allergan plc: 171,100 shares worth $46.5M.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 24% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $45M trimmed.
- Polar Capital's largest Q3 2015 buy was Allergan plc: 171,100 shares worth $46.5M.
- Polar Capital added most to UnitedHealth in Q3 2015, an estimated $48.5M increase.
- Polar Capital's biggest Q3 2015 reduction was Thermo Fisher Scientific, cutting an estimated $45M.
- Polar Capital fully exited Time Warner Inc in Q3 2015, selling an estimated $55.2M.
- Polar Capital's ten largest holdings make up 23% of its $4.94B portfolio in Q3 2015.
- Polar Capital opened 46 new positions and closed 39 in Q3 2015.
- Polar Capital's portfolio value fell 4.9% quarter-over-quarter to $4.94B.
Based on Polar Capital's 13F filing for Q3 2015, filed 16 Nov 2015.